Photobiomodulation for Dry Age-Related Macular Degeneration

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)

Recruiting Observational Study
Dry Age-related Macular Degeneration
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
LumiThera, Inc. · Industry
Who this trial is looking for

This trial is looking for adults with dry age-related macular degeneration. By participating, you will help researchers collect information about the safety and effectiveness of a light treatment used for this condition.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with dry age-related macular degeneration.
  • I can communicate well and understand what the study involves.
  • I have given my written consent to take part in the study.

You may not be able to join if

  • I have geographic atrophy that involves my center of vision.
  • I have neovascular maculopathy.
  • I have used any light-activating medications in the past 30 days without consulting my doctor.
  • I am known to be sensitive to yellow light, red light, or near infrared light.
  • I have a history of light-activated central nervous system disorders.
  • I am unlikely to follow the study guidelines according to the investigator.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively. PBM involves the use of visible light …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator; 2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study; 3. Informed of the nature of this study and has provided written, informed consen…
Contacts

Alcon Call Center

1-888-451-3937

alcon.medinfo@alcon.com

CONTACT